By targeting vascular endothelial growth factor receptor (VEGFR) to impede tumor angiogenesis, they have become a predominant treatment modality for numerous solid malignant tumors (Ciccarese et al., 2021; Du et al., 2022). This evidence concerns the gene KDR and neoplasm.